Mithra Signs LSA for Commercialization of Myring™ in Germany, the biggest market in Europe

  • Mithra grants exclusive license to Hormosan for commercialization of vaginal contraceptive ring in Germany
  • Germany is the largest European market in terms of volumes, with 3 million vaginal rings sold per year
  • Agreement follows licensing deals for Myring™ with market leaders in the U.S., Europe, Russia, Australia, Middle East, Latin and South America

Liege, Belgium, 28 May 2019 – 7 :30  CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has entered into an exclusive license and supply agreement with Hormosan for the commercialization of its hormonal contraceptive ring Myring™, bioequivalent to Nuvaring®, in Germany. Hormosan is a subsidiary of the innovation-driven pharmaceutical company Lupin Group, offering low-cost generics in Germany that offer added value relevant to therapy.

Tibelia®, First Tibolone-Based Hormone Therapy Approved in Canada

  • The Canadian Health authorities have granted the Marketing Authorization for Tibelia®, the company’s tibolone-based product for use in Hormone Therapy (HT).
  • First tibolone-based hormone treatment to be available in Canada, offering a true new option for women with a proven efficacy, tolerability and safety profile
  • The introduction of Tibelia® in Canada plays a crucial role in the international commercial expansion strategy in key attractive markets like the United States

Liege, Belgium, 15 May 2019 – 7 :30  CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that Health Canada, the Canadian Health authorities, has approved Tibelia® (tibolone), indicated for the short-term treatment of vasomotor symptoms due to estrogen deficiency in postmenopausal women, more than one year after menopause. Developed by Mithra as bioequivalent version of Livial®, Tibelia® is a synthetic steroid that relieves postmenopausal symptoms and prevents osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products.